Contact | Print version | PDF version | Send article | RSS-Feed

Jado Technologies licences clinical data from Æterna Zentaris for use of Miltefosine in allergy indications

01 Nov 2007 - Dresden based biotech JADO Technologies today signed an agreement with Aeterna Zentaris for access to clinical data for the marketed drug miltefosine. JADO believes its proprietary technology is able to identify additional indications for the drug, in this case for allergy disorders. JADO is focused on an area of the cell membrane called RAFTs. The Company believes that these subcompartments play a key role in the signaling pathway of cells. By targeting RAFTS they hope to be able to stop the disease process.
 
JADO Technologies announced the licensing of exclusive access to preclinical and clinical data on miltefosine from Æterna Zentaris Inc. for development of the compound in allergy indications. Access to this data could potentially streamline the clinical development of miltefosine in allergy. Financial terms were not disclosed.
 
Utilizing its proprietary RAFT Intervention Technologies®, JADO conducted screening of marketed compound libraries for suitable candidates that are able to modulate cell membrane RAFTs. RAFTs are sub-compartments of the cell membrane that play a key role in physiological processes. This new insight into cell membrane chemistry revealed that the anticancer agent miltefosine may have additional therapeutic properties. JADO is conducting studies with miltefosine in cutaneous mastocytosis, atopic dermatitis and urticaria. Under the terms of the agreement, Æterna Zentaris will supply miltefosine to JADO for use in clinical trials. Miltefosine is currently marketed by Æterna Zentaris under the trade name Impavido® for the treatment of leishmaniasis. In addition, it is marketed by Baxter under the trade name Miltex® for the treatment of metastatic breast cancer.